Just a few short months after Johnson & Johnson’s Janssen unit sent its targeted non-small cell lung cancer drug amivantamab to the FDA, the regulator has come back with a green light—a very specific one. Now christened Rybrevant, the drug is the first-ever treatment for non-small cell lung cancer with a group of epidermal growth factor receptor (EGFR) mutations found in… Read More »
While he welcomed the milestone, he added: “As we set out in our recent briefing, we need to see more progress on vaccines, lower Covid-19 case numbers, much less pressure on the NHS and plans in place to contain future outbreaks before easing restrictions. BBC News – Health
Timothy Ray Brown, the first person to be cured of H.I.V., through an experimental bone marrow transplant that offered hope though not a realistic treatment for most people with the virus, died on Tuesday at his home in Palm Springs, Calif. He was 54. His partner, Tim Hoeffgen, said the cause was unrelated recurring leukemia.… Read More »
Have you ever been turned on by the sex scenes in movies? You’d be lying if you said no. The idea of your hot, writhing, sexy bodies rubbing against each other can be quite an arousing thought and why not? But, do you know that it takes quite some time for you to get there… Read More »
Print this page HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] Tremfya is the first treatment… Read More »